Pfizer's acquisition of Wyeth, discussed in the chapter Strategic Focus, should be driven by defensive reasons (e.g., to gain sales revenue) rather than strategic reasons (e.g., cost and revenue synergy).

Question

Quizplus · Accepted Answer

The statement is incorrect. Pfizer's acquisition of Wyeth was driven by strategic reasons, such as cost and revenue synergy through the combination of their complementary product portfolios and R&D pipelines, as well as gaining access to Wyeth's established presence in emerging markets. While gaining sales revenue may have been a factor, it was not the primary driver of the acquisition.

Pfizer's Acquisition of Wyeth, Discussed in the Chapter Strategic Focus